Replimune GroupFRA:7R8 -3.56%32 Current Ratio is 4.79 as of Mar. 2026, which is 64% below its 10-year median of 13.40. GuruFocus rates FRA:7R8 with a GF Score™ of 32/100. The stock has 4 warning signs investors should review. Among 1,410 Biotechnology companies, Replimune Group ranks better than 56.52% on this metric.
The current ratio is a liquidity ratio that measures a company's ability to pay short-term obligations. It is calculated as a company's Total Current Assets divides by its Total Current Liabilities. Replimune Group's current ratio for the quarter that ended in Mar. 2026 was 4.79.
Replimune Group has a current ratio of 4.79. It indicates the company may not be efficiently using its current assets or its short-term financing facilities. This may also indicate problems in working capital management.
The historical rank and industry rank for Replimune Group's Current Ratio or its related term are showing as below:
FRA:7R8'
s Current Ratio Range Over the Past 10 Years
Min: 4.79 Med: 13.4 Max: 33.25
Current: 4.79
During the past 10 years, Replimune Group's highest Current Ratio was 33.25. The lowest was 4.79. And the median was 13.40.
FRA:7R8's Current Ratio is ranked better than 56.52% of 1410
companies
in the Biotechnology industry
Industry Median: 3.89
vs FRA:7R8: 4.79
Replimune Group (FRA:7R8) Current Ratio Explanation
The current ratio can give a sense of the efficiency of a company's operating cycle or its ability to turn its product into cash. Companies that have trouble getting paid on their receivables or have long inventory turnover can run into liquidity problems because they are unable to alleviate their obligations. Because business operations differ in each industry, it is always more useful to compare companies within the same industry.
Acceptable current ratios vary from industry to industry and are generally between 1 and 3 for healthy businesses.
The higher the current ratio, the more capable the company is of paying its obligations. A ratio under 1 suggests that the company would be unable to pay off its obligations if they came due at that point. While this shows the company is not in good financial health, it does not necessarily mean that it will go bankrupt - as there are many ways to access financing - but it is definitely not a good sign.
If all other things were equal, a creditor, who is expecting to be paid in the next 12 months, would consider a high current ratio to be better than a low current ratio, because a high current ratio means that the company is more likely to meet its liabilities which fall due in the next 12 months.
Replimune Group Current Ratio Related Terms
Replimune Group Current Ratio Historical Data
* Premium members only.
The historical data trend for Replimune Group's Current Ratio can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
FRA:7R8 vs AVTX, KURA, SANA: Current Ratio Comparison
For the Biotechnology subindustry, Replimune Group's Current Ratio, along with its competitors' market caps and Current Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Replimune Group Current Ratio vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Replimune Group's Current Ratio distribution charts can be found below:
* The bar in red indicates where Replimune Group's Current Ratio falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Replimune Group (FRA:7R8) has a Current Ratio of 4.79 as of Mar. 2026. This is 64% below median its historical median of 13.40. Over the past decade, Replimune Group's Current Ratio has ranged from 4.79 to 33.25. According to the industry distribution chart, Replimune Group ranks #613 out of 1410 companies in the Biotechnology industry, placing it in the top 43.5%.
Is Replimune Group's Current Ratio too high?
Replimune Group's current Current Ratio of 4.79 is 64% below median its 10-year median of 13.40. Over the past 10 years, this metric has ranged from a low of 4.79 to a high of 33.25. The Biotechnology industry median Current Ratio is 3.89. Replimune Group's value of 4.79 is 23.1% above this industry median. Based on the distribution chart, Replimune Group ranks #613 out of 1410 companies in the Biotechnology industry, which is above the industry midpoint. Overall, Replimune Group has a GF Score™ of 32/100, reflecting its overall financial health beyond just this single metric.
How does Replimune Group's Current Ratio compare to AVTX and KURA?
According to the Biotechnology industry distribution chart, Replimune Group ranks #613 out of 1410 companies for Current Ratio. This puts Replimune Group in the upper half of its industry. The industry median Current Ratio is 3.89. Replimune Group's value of 4.79 is 23.1% above this benchmark. Historically, Replimune Group's own Current Ratio has ranged from 4.79 to 33.25 over the past decade. While the company's 10-year median is 13.40 vs. the industry median of 3.89, Replimune Group has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Current Ratio for a Biotechnology company?
The median Current Ratio among Biotechnology companies is 3.89, based on 1,410 companies in the industry. Companies in the top quartile (top 25%) have a Current Ratio significantly above this median, while those in the bottom quartile fall well below. However, Current Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Replimune Group's current Current Ratio of 4.79 is 23.1% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Current Ratio mean?
A high Current Ratio can signal that a stock is expensive relative to its fundamentals. For the Biotechnology industry, the median Current Ratio is 3.89 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Replimune Group's current Current Ratio is 4.79, which is 64% below median its own 10-year median of 13.40. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Replimune Group stock overvalued right now?
Replimune Group (FRA:7R8) has a current Current Ratio of 4.79. The current Current Ratio is 4.79, which is 64% below median its 10-year median of 13.40 and 23.1% above the Biotechnology industry median of 3.89. Replimune Group's overall GF Score™ is 32/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Current Ratio calculated?
Current Ratio is calculated from a company's financial statements. For Replimune Group (FRA:7R8), the current Current Ratio is 4.79 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Replimune Group Inc is a clinical-stage biotechnology company. It uses a proprietary RPx platform to design and develop product candidates that are intended to maximally activate the immune system against solid tumors. The RPx platform is based on a proprietary, engineered strain of herpes simplex virus 1, or HSV-1, backbone with payloads added to maximize immunogenic cell death and the induction of a systemic anti-tumor immune response. The company focuses on developing oncolytic immunotherapies for the treatment of cancer. Its pipeline products include RP1, RP2, and RP3. The company operates in USA and UK, majority of revenue from USA.
32GF Score
Get the complete analysis for FRA:7R8
Current Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
FRA:7R8 has been successfully added to your 
